Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses

This publication has 29 references indexed in Scilit:

• Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines
  Vaccine, 2011
• Viral Mutation Rates
  Journal of Virology, 2010
• Substitution of Wild‐Type Yellow Fever Asibi Sequences for 17D Vaccine Sequencesin ChimeriVax–Dengue 4 Does Not Enhance Infection ofAedes aegyptiMosquitoes
  The Journal of Infectious Diseases, 2008
• Adaptation of two flaviviruses results in differences in genetic heterogeneity and virus adaptability
  Journal of General Virology, 2007
• Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All
  Human Vaccines, 2006
• Long-Term Transmission of Defective RNA Viruses in Humans and Aedes Mosquitoes
  Science, 2006
• A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys
  Journal of Virology, 2004
• Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells
  Vaccine, 2003
• Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine
  Journal of General Virology, 1995
• Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213
  Virus Research, 1995